Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 6829-6837

  Takano, Toshimi ^a   Ohe, Yuichiro ^a   Sakamoto, Hiromi ^a   Tsuta, Koji ^a   Matsuno, Yoshihiro ^a   Tateishi, Ukihide ^a   Yamamoto, Seiichiro ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Sekine, Ikuo ^a   Kunitoh, Hideo ^a   Shibata, Tatsuhiro ^a   Sakiyama, Tokuki ^a   Yoshida, Teruhiko ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; ANTINEOPLASTIC AGENT; DNA; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DNA EXTRACTION; DRUG SENSITIVITY; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MONOTHERAPY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; TREATMENT OUTCOME; GENE DOSAGE; GENETICS; LUNG TUMOR; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PREDICTION AND FORECASTING; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE DOSAGE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 27244451321     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.0793     Document Type: Article

References (31)

1. Fukuoka M, Yano S, Giaccone G, et al: A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-2246, 2003
2. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
3. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004
4. Takano T, One Y, Kusumoto M, et al: Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45:93-104, 2004
5. Kim YH, Ishii G, Goto K, et al: Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 10:7311-7317, 2004
6. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
7. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
8. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
9. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004
10. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203, 2004
11. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005
12. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857-865, 2005
13. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167-1173, 2005
14. Noguchi M, Furuya S, Takeuchi T, et al: Modification formalin and methanol fixation methods for molecular biological and morphological analyses. Pathol Int 47:685-691, 1997
15. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807, 2003
16. Capuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
17. Stephens P, Hunter C, Bignell G, et al: Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004
18. Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646, 2005
19. Cappuzzo F, Magrini E, Ceresoli GL, et al: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96:1133-1141, 2004
20. Han SW, Hwang PG, Chung DH, et al: Epidermal growth factor receptor (EGFR) down-stream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy resistant non-small-cell lung cancer. Int J Cancer 113:109-115, 2005
21. Franklin WA, Chansky K, Gumerlock PH, et al: Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). J Clin Oncol 22:618, 2004 (suppl; abstr 7015)
22. Emmert-Buck MR, Bonner RF, Smith PD, et al: Laser capture microdissection. Science 274:998-1001, 1996
23. Maeno G, Isobe T, Tokoro Y, et al: NAMIHEI: A novel algorithm for genomic polymorphism detection from DNA sequence. Genome Informatics 14:595-596, 2003
24. Ronaghi M: Pyrosequencing sheds light on DNA sequencing. Genome Res 11:3-11, 2001
25. Travis WD, Colby TV, Corrin B, et al: Histologic Typing of Tumors of Lung and Pleura: World Health Organization International Classification of Tumors (ed 3). New York, NY, Springer Verlag, 1999
26. Ebright M, Zakowski M, Martin J, et al: Clinical pattern and pathological stage but not histological features predict outcomes for bronchioloalveolar carcinoma (BAC). Ann Thorac Surg 74:1640-1646, 2002
27. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
28. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
29. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
30. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
31. Thatcher N, Chang A, Parikh P, et al: Results of a phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. Proc Am Assoc Cancer Res 46, 2005 (abstr LB-6)